Reduced tissue parasitic load and infectivity to sand flies in dogs naturally infected by Leishmania (Leishmania) chagasi following treatment with a liposome formulation of meglumine antimoniate

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 7, 2008, Pages 2564-2572

  Ribeiro, Raul R ^a   Moura, Eliane P ^a   Pimentel, Vitor M ^a   Sampaio, Weverton M ^a   Silva, Sydnei M ^a   Schettini, Dante A ^a   Alves, Cintia F ^a   Melo, Ferdinan A ^a   Tafuri, Wagner L ^a   Demicheli, Cynthia ^a   Melo, Maria N ^a   Frézard, Frédéric ^a   Michalick, Marilene S M ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY; LIPOSOME; MEGLUMINE ANTIMONATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; BRAZIL; CERVICAL LYMPH NODE; CONTROLLED STUDY; DEFECATION; DOG; DRUG EFFECT; DRUG FORMULATION; ENDEMIC DISEASE; HYPERSALIVATION; IMMUNOCYTOCHEMISTRY; KIDNEY FUNCTION; LEISHMANIA CHAGASI; LIVER; LIVER FUNCTION; NONHUMAN; PARASITE CONTROL; PRIORITY JOURNAL; PSYCHODIDAE; SKIN; SPLEEN; TACHYPNEA; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIPROTOZOAL AGENTS; DOG DISEASES; DOGS; FEMALE; INSECT VECTORS; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; LIPOSOMES; MALE; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; PHLEBOTOMUS;

EID: 46249112772     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00223-08     Document Type: Article

References (46)

1. Alexander, A., and D. G. Russel. 1992. The interaction of Leishmania species with macrophages. Adv. Parasitol. 31:175-254.
2. Alvar, J., R. Molina, M. San Andrés, M. Tesouro, J. Nieto, M. Vitutia, F. Gonzalez, M. D. San Andrés, J. Boggio, F. Rodriguez, A. Sainz, and C. Escacena. 1994. Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy. Ann. Trop. Med. Parasitol. 88:371-378.
3. Alving, C. R., and E. A. Steck. January 1980. Liposome carriers in chemotherapy of leishmaniasis. U.S. patent 4,186,183.
4. Alving, C. R., E. A. Steck, W. L. Chapman, Jr., V. B. Waits, L. D. Hendricks, G. M. Swartz, and W. L. Hanson. 1980. Liposomes in leishmaniasis: therapeutic effects of antimonial drugs, 8-aminoquinolines, and tetracyclines. Life Sci. 26:2231-2238.
5. Alving, C. R. 1986. Liposomes as drug carriers in leishmaniasis and malaria. Parasitol. Today 2:101-107.
6. Amusategui, I. 1998. Tratamiento de la leishmaniosis canina: valoración, caracterización y comparación de la respuesta a distintos protocolos a basc de Antimoniato de meglumina asociado o no al Alopurinol. Ph.D. thesis. Universidad Complutense de Madrid, Madrid, Spain.
7. Baillie, A. J., G. H. Coombs, T. F. Dolan, and J. Laurie. 1986. Nonionic surfactant vesicles, niosomes, as a delivery system for the antileishmanial drug sodium stibogluconate. J. Pharm. Pharmacol. 38:502-505.
8. Banduwardene, R., A. B. Mullen, and K. C. Carter. 1997. Immune responses of Leishmania donovani infected BALB/c mice following treatment with free and vesicular sodium stibogluconate formulations. Int. J. Immunopharmacol. 19:195-203.
9. Berman, J. D. 1997. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin. Infect. Dis. 24: 684-703.
10. Bhowmick, S., R. Ravindran, and N. Ali. 2008. Gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani. Infect. Immun. 76:1003-1015.
11. Carter, K. C., A. J. Baillie, J. Alexander, and T. F. Dolan. 1988. The therapeutic effect of sodium stibogluconate in BALB/c mice infected with Leishmania donovani is organ-dependent. J. Pharm. Pharmacol. 40:370-373.
12. Chapman, W. L., W. L. Hanson, C. R. Alving, and L. D. Hendricks. 1984. Antileishmanial activity of liposome-encapsulated meglumine antimonate in the dog. Am. J. Vet. Res. 45:1028-1030.
13. Collins, M., K. C. Carter, A. J. Baillie, and J. O'Grady. 1993. The distribution of free and non-ionic vesicular sodium stibogluconate in the dog. J. Drug Targeting 1:133-142.
14. Costa-Val, A. P. 2004. Tratamento da leishmaniose visceral canina com antimonial pentavalente encapsulado em lipossomas. Ph.D. thesis. Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
15. da Costa-Val, A. P., R. R. Cavalcanti, N. F. Gontijo, M. S. M. Michalick, B. Alexander, P. Williams, and M. N. Melo. 2007. Canine visceral leishmaniasis: relationships between clinical status, humoral immune response, haematology and Lutzomyia (Lutzomyia) longipalpis infectivity. Vet. J. 174:636-643.
16. Demicheli, C., T. L. de Figueiredo, S. Carvalho, R. D. Sinisterra, J. C. D. Lopes, and F. Frézard. 1999. Physico-chemical characterization of meglumine antimoniate. Biometals 12:63-66.
17. Demicheli, C., R. Ochoa, I. S. Lula, F. C. Gozzo, M. Eberlin, and F. Frézard. 2003. Pentavalent organoantimonial derivatives: two simple and efficient synthetic methods for meglumine antimonate. Appl. Organomet. Chem. 17:226-231.
18. Demicheli, C., and F. Frézard. 2005. Pentavalent antimonials: from chemistry to the design of new drugs. Drug Design Rev. 2:243-249. http://www.bentham.org/ddro/.
19. Frézard, F., M. S. M. Michalick, C. F. Soares, and C. Demicheli. 2000. Novel methods for the encapsulation of meglumine antimoniate in liposomes. Braz. J. Med. Biol. Res. 33:841-846.
20. Frézard, F., D. Schettini, O. G. F. Rocha, and C. Demicheli. 2005. Liposomes: physicochemical and pharmacological properties, applications in antimony-based chemotherapy. Quim. Nova 28:511-518.
21. Gradoni, L., M. Maroli, M. Grammicia, and F. Mancianti. 1987. Leishmania infantum infection rates in Phlebotomus perniciosus fed on naturally infected dogs under antimonial treatment. Med. Vet. Entomol. 1:339-342.
22. Guarga, J. L., J. Moreno, J. Lucientes, M. J. Gracia, M. A. Peribanez, J. Alvar, and J. A. Castillo. 2000. Canine leishmaniasis transmission: higher infectivity amongst naturally infected dogs to sand flies is associated with lower proportions of T helper cells. Res. Vet. Sci. 69:249-253.
23. Hwang, K. J. 1987. Liposome pharmacokinetics, p. 109-156. In M. J. Ostro (ed.), Liposomes: from biophysics to therapeutics, Marcel Dekker, Inc., New York, NY.
24. Johnson, P. T., E. McConnell, and M. Hertig. 1963. Natural infection of leptomonad flagellates in Panamanian Phlebotomus sandflies. Exp. Parasitol. 14:107-122.
25. Lima, W. G., P. S. Oliveira, M. V. Caliari, R. Goncalves, M. S. M. Michalick, M. N. Melo, W. L. Tafuri, and W. L. Tafuri. 2007. Histopathological and immunohistochemical study of type 3 complement receptors (CD11b/CD18) in livers and spleens of asymptomatic and symptomatic dogs naturally infected with Leishmania (Leishmania) chagasi. Vet. Immunol. Immunopathol. 117:129-136.
26. Mancianti, F., M. Gramiccia, I. Gradoni, and S. Pieri. 1988. Studies on canine leishmaniais control. 1. Evolution of infection of different clinical forms of canine leishmaniasis following antimonial treatment. Trans. R. Soc. Trop. Med. Hyg. 82:566-567.
27. Meyerhoff, A. 1999. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin. Infect. Dis. 28:42-51.
28. Molina, R., C. Amela, J. Nieto, M. San Andrés, F. González, J. A. Castillo, J. Lucientes, and J. Alvar. 1994. Infectivity of dogs naturally infected with Leishmania infantum to colonized Phlebotomus perniciosus. Trans. R. Soc. Trop. Med. Hyg. 88:491-493.
29. National Institutes of Health. 1985. Principles of laboratory animal care. Publication 85-23. National Institutes of Health, Bethesda, MD.
30. New, R. R. C., M. L. Chance, and S. Heath. 1981. Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. J. Antimicrob. Chemother. 8:371-381.
31. Nieto, J., J. Alvar, A. B. Mullen, K. C. Carter, C. Rodríguez, M. I. San Andrés, M. D. San Andrés, A. J. Baillie, and F. González. 2003. Pharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animals. Antimicrob. Agents Chemother. 47: 2781-2787.
32. Noli, C. 1999. Canine leishmaniasis. Waltham Focus 9:16-24.
33. Noli, C., and S. T. Auxilia. 2005. Treatment of canine Old World visceral leishmaniasis: a systematic review. Vet. Dermatol. 16:213-232.
34. Oliva, G., L. Gradoni, P. Ciaramella, R. De Luna, L. Cortese, S. Orsini, R. N. Davidson, and A. Persechino. 1995. Activity of liposomal amphotericin B (AmBisome) in dogs naturally infected with Leishmania infantum J. Antimicrob. Chemother. 36:1013-1019.
35. Oliveira, F. B., D. A. Schettini, C. S. Ferreira, B. Rates, O. G. F. Rocha, F. Frézard, and C. Demicheli. 2006. Kinetics of antimony (V) reduction by L-cysteine. Pharmacological implications and application to the determination of antimony in pentavalente antimonial drugs. J. Braz. Chem. Soc. 17:1642-1650.
36. Rao, L. S. June 1986. Anti-leishmanial pharmaceutical formulation. U.S. patent 4,594,241.
37. Schettini, D. A., A. P. Costa-Val, L. F. Souza, C. Demicheli, O. G. F. Rocha, M. N. Melo, M. S. M. Michalick, and F. Frézard. 2003. Distribution of liposome-encapsulated antimony in dogs. Braz. J. Med. Biol. Res. 36:269-272.
38. Schettini, D. A., A. P. Costa-Val, L. F. Souza, C. Demicheli, O. G. F. Rocha, M. N. Melo, M. S. M. Michalick, and F. Frézard. 2005. Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate. Braz. J. Med. Biol. Res. 38:1879-1883.
39. Schettini, D. A., R. R. Ribeiro, C. Demicheli, O. G. F. Rocha, M. N. Melo, M. S. M. Michalick, and F. Frézard. 2006. Improved targeting of antimony to the bone marrow of dogs using liposomes of reduced size. Int. J. Pharm. 315:140-147.
40. Slappendel, R. J. 1988. Canine leishmaniasis. A review based on 95 cases in the Netherlands. Vet. Q. 10:1-16.
41. Szebeni, J. 1998. The interaction of liposomes with the complement system. Crit. Rev. Ther. Drug Carrier Syst. 15:57-88.
42. Szebeni, J., L. Baranyi, S. Savay, M. Bodo, D. S. Morse, M. Basta, G. L. Stahl, R. Bunger, and C. R. Alving. 2000. Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction. Am. J. Physiol. Heart Circ. Physiol. 279:1319-1328.
43. Tafuri, W. L., R. L. Santos, R. M. E. Arantes, R. Gonçalves, M. N. Melo, M. S. M. Michalick, and W. L. Tafuri. 2004. Na alternative immunohistochemical method for detecting Leishmania amastigotes in paraffin-embedded canine tissues. J. Immunol. Methods 292:17-23.
44. Travi, B. L., C. J. Tabares, H. Cadena, C. Ferro, and Y. Osorio. 2001. Canine visceral leishmaniasis in Colombia: relationship between clinical and parasitologic status and infectivity for sand flies. Am. J. Trop. Med. Hyg. 64:119-124.
45. Valladares, J. E., J. Freixas, J. Alberola, C. Franquelo, C. Cristofol, and M. Arboix. 1997. Pharmacokinetics of liposome-encapsulated meglumine antimoniate after intramuscular and subcutaneous administration in dogs. Am. J. Med. Hyg. 57:403-406.
46. Valladares, J. E., C. Riera, P. González-Ensenyat, A. Díez-Cascón, G. Ramos, L. Solano-Gallego, M. Gállego, M. Gállego, N. Portús, M. Arboix, and J. Alberola. 2001. Long term improvement in the treatment of canine leishmaniosis using antimony liposomal formulation. Vet. Parasitol. 97:15-21.